<DOC>
	<DOCNO>NCT01314885</DOCNO>
	<brief_summary>A single dose study inhale anti-inflammatory agent PF-03715455 establish anti-inflammatory activity follow challenge LPS . Inhaled LPS invoke acute inflammatory response lung see induced sputum . PH-0797804 internal control study .</brief_summary>
	<brief_title>Single Dose Lipopolysaccharide ( LPS ) Study In Healthy Volunteers</brief_title>
	<detailed_description>Proof Mechanism</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male female ( nonchild bear potential ) subject , age 1850 year . Subjects whose FEV1 FVC screen great equal 80 % predict value age , race , sex height . Subjects normoresponsive airway . Subjects able successfully complete screen sputum induction . Subjects evidence , review prestudy laboratory data full physical examination , history clinically significant hematological , renal , endocrine , gastrointestinal , dermatological , hepatic , psychiatric , neurologic disease . Specifically liver function test CRP must within reference range . Subjects medical history asthma symptomatology ( ie , wheeze and/or dyspnea rest ) . Subjects experience respiratory tract infection within previous 4 week infection within 1 week dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Healthy</keyword>
</DOC>